Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Servier
Eli Lilly and Company
Turning Point Therapeutics, Inc.
AstraZeneca
Sotio Biotech Inc.
Erasca, Inc.
Arvinas Inc.
xCures
Adela, Inc
Eli Lilly and Company
Degron Therapeutics Co.
Bayer
Actym Therapeutics, Inc.
Merck Sharp & Dohme LLC
Ikena Oncology
Sensei Biotherapeutics, Inc.
Apollomics Inc.
ModeX Therapeutics, An OPKO Health Company
TransThera Sciences (Nanjing), Inc.
Hoffmann-La Roche
Xynomic Pharmaceuticals, Inc.
Taproot Health
VitaMed Research LLC
Salubris Biotherapeutics Inc
NantCell, Inc.
ABM Therapeutics Corporation
TransThera Sciences (Nanjing), Inc.
Hoffmann-La Roche
Kineta Inc.
Blue Note Therapeutics
MacroGenics
Fore Biotherapeutics
Lumos Pharma
Pfizer
Amgen
Novartis
Valerio Therapeutics
Valerio Therapeutics
Calando Pharmaceuticals
Mannkind Corporation